Health Economics›Non-small cell lung cancer›Definitive therapy for locally advanced disease

Definitive therapy for locally advanced disease

Non-small cell lung cancer · 11 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 1 point

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
MVP and RT Variant #01 Partial	—	R 4 249	46d	—	~20.5 mo	—	—	—
Carboplatin and Paclitaxel (CP) and RT Variant #01	—	R 3 785	35d	—	~18.2 mo	—	—	1
Cisplatin, Pemetrexed, RT Variant #01	—	R 3 263	63d	—	—	—	—	—
Cisplatin, Vinblastine, RT Variant #01	—	R 2 228	35d	—	—	—	—	—
Carboplatin, Vinorelbine, RT Variant #01	—	R 2 192	21d	—	~12.6 mo	—	—	—
Cisplatin and Vinorelbine (CVb) and RT Variant #01	—	R 1 722	42d	—	—	—	—	1
Carboplatin and RT Variant #01	—	R 1 516	42d	—	~22.4 mo	—	—	1
Cisplatin and RT Variant #01	—	R 1 500	49d	~5.3 mo	—	~4	~R 6 001 PFS proxy · indirect	—
Cisplatin and Docetaxel (DC) and RT N/A - secondary systemic drug	—	R 176	—	—	—	—	—	—
Cisplatin, Etoposide, RT Partial	—	—	—	—	—	—	—	—
Radiation therapy N/A - radiation Partial	—	—	49d	~5.1 mo	~12.0 mo	~4	—	1

11 of 11 regimens shown